Is DMAC or RANI more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Rani Therapeutics N/A -104.60% -65.17%

Does the media favor DMAC or RANI?

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 1.50 beat Rani Therapeutics' score of -0.71 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is TECX or RANI more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Rani Therapeutics N/A -104.60% -65.17%

Does the media favor TECX or RANI?

In the previous week, Tectonic Therapeutic had 5 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Tectonic Therapeutic and 1 mentions for Rani Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.36 beat Rani Therapeutics' score of -0.71 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer PRTC or RANI?

Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 979.18%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has preferable valuation & earnings, PRTC or RANI?

Rani Therapeutics has lower revenue, but higher earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Rani Therapeutics $1.63M 69.34 -$29.67M -$0.27 N/A

Is PRTC or RANI more profitable?

PureTech Health's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Rani Therapeutics N/A -104.60% -65.17%

Does the media prefer MYGN or RANI?

In the previous week, Myriad Genetics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for Rani Therapeutics. Myriad Genetics' average media sentiment score of 0.61 beat Rani Therapeutics' score of -0.71 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Is RANI or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% Zura Bio N/A -56.13% -50.15%

Does the media favor RANI or ZURA?

In the previous week, Zura Bio had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Rani Therapeutics. Zura Bio's average media sentiment score of 0.45 beat Rani Therapeutics' score of -0.71 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Zura Bio 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rani Therapeutics (RANI) Competitors

$0.81 +0.02 (+1.92%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.09%)

As of 10/2/2026 07:30 PM Eastern

Compare

RANI vs. DMAC, TECX, PRTC, MYGN, and ZURA

Should you buy Rani Therapeutics stock or one of its competitors? Rani Therapeutics's main competitors and comparable companies include DiaMedica Therapeutics (DMAC), Tectonic Therapeutic (TECX), PureTech Health (PRTC), Myriad Genetics (MYGN), and Zura Bio (ZURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rani Therapeutics compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

DiaMedica Therapeutics' return on equity of -77.76% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Rani Therapeutics	N/A	-104.60%	-65.17%

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rani Therapeutics has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Rani Therapeutics	$1.63M	69.34	-$29.67M	-$0.27	N/A

DiaMedica Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

DiaMedica Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 45.81%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 979.18%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, DiaMedica Therapeutics and DiaMedica Therapeutics both had 1 articles in the media. DiaMedica Therapeutics' average media sentiment score of 1.50 beat Rani Therapeutics' score of -0.71 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Rani Therapeutics beats DiaMedica Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Rani Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Tectonic Therapeutic has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Rani Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Rani Therapeutics	$1.63M	69.34	-$29.67M	-$0.27	N/A

Tectonic Therapeutic presently has a consensus target price of $77.80, indicating a potential upside of 245.16%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 979.18%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Tectonic Therapeutic had 5 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Tectonic Therapeutic and 1 mentions for Rani Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.36 beat Rani Therapeutics' score of -0.71 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic's return on equity of -35.26% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Tectonic Therapeutic beats Rani Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to PureTech Health?

PureTech Health (NASDAQ:PRTC) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 979.18%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Rani Therapeutics had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Rani Therapeutics and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.08 beat Rani Therapeutics' score of -0.71 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Rani Therapeutics	Negative

PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Rani Therapeutics has lower revenue, but higher earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Rani Therapeutics	$1.63M	69.34	-$29.67M	-$0.27	N/A

PureTech Health's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Rani Therapeutics beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does Rani Therapeutics compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rani Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A
Rani Therapeutics	$1.63M	69.34	-$29.67M	-$0.27	N/A

In the previous week, Myriad Genetics had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for Rani Therapeutics. Myriad Genetics' average media sentiment score of 0.61 beat Rani Therapeutics' score of -0.71 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Myriad Genetics currently has a consensus price target of $3.93, suggesting a potential downside of 13.36%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 979.18%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rani Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Rani Therapeutics beats Myriad Genetics on 10 of the 17 factors compared between the two stocks.

How does Rani Therapeutics compare to Zura Bio?

Rani Therapeutics (NASDAQ:RANI) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Zura Bio had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Zura Bio and 1 mentions for Rani Therapeutics. Zura Bio's average media sentiment score of 0.45 beat Rani Therapeutics' score of -0.71 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Zura Bio	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio's return on equity of -56.13% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Zura Bio	N/A	-56.13%	-50.15%

Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Rani Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 979.18%. Zura Bio has a consensus target price of $17.00, indicating a potential upside of 313.63%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rani Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	69.34	-$29.67M	-$0.27	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Summary

Rani Therapeutics and Zura Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$113.02M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-3.00	13.06	275.67	26.04
Price / Sales	69.34	1,292.17	656.66	110.58
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	2.38	16.63	10.93	6.31
Net Income	-$29.67M	-$22.71M	$3.51B	$362.16M
7 Day Performance	6.80%	-2.99%	-2.00%	-1.66%
1 Month Performance	-6.30%	-10.81%	-6.19%	-4.68%
1 Year Performance	60.55%	19.19%	8.03%	1.57%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	2.6067 of 5 stars	$0.81 +1.9%	$8.75 +979.2%	+60.6%	$113.02M	$1.63M	N/A	69
DMAC DiaMedica Therapeutics	2.0184 of 5 stars	$8.23 -1.5%	$12.00 +45.9%	+16.4%	$443.68M	N/A	N/A	35	Positive News
TECX Tectonic Therapeutic	2.4404 of 5 stars	$22.65 -0.1%	$77.80 +243.5%	+47.9%	$441.58M	N/A	N/A	60	News Coverage Positive News Analyst Forecast
PRTC PureTech Health	0.0696 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	Positive News
MYGN Myriad Genetics	1.0591 of 5 stars	$4.35 +7.0%	$3.93 -9.5%	-43.7%	$414.64M	$824.50M	N/A	2,700	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. DMAC, TECX, PRTC, MYGN, and ZURA

How does Rani Therapeutics compare to DiaMedica Therapeutics?

Summary

How does Rani Therapeutics compare to Tectonic Therapeutic?

Summary

How does Rani Therapeutics compare to PureTech Health?

Summary

How does Rani Therapeutics compare to Myriad Genetics?

Summary

How does Rani Therapeutics compare to Zura Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. DMAC, TECX, PRTC, MYGN, and ZURA

How does Rani Therapeutics compare to DiaMedica Therapeutics?

Is DMAC or RANI more profitable?

Do insiders & institutionals believe in DMAC or RANI?

Which has higher valuation & earnings, DMAC or RANI?

Which has more risk & volatility, DMAC or RANI?

Do analysts recommend DMAC or RANI?

Does the media favor DMAC or RANI?

Summary

How does Rani Therapeutics compare to Tectonic Therapeutic?

Which has more volatility & risk, TECX or RANI?

Which has preferable earnings and valuation, TECX or RANI?

Do analysts recommend TECX or RANI?

Does the media favor TECX or RANI?

Do institutionals and insiders have more ownership in TECX or RANI?

Is TECX or RANI more profitable?

Summary

How does Rani Therapeutics compare to PureTech Health?

Do analysts prefer PRTC or RANI?

Do insiders & institutionals have more ownership in PRTC or RANI?

Does the media prefer PRTC or RANI?

Which has more volatility and risk, PRTC or RANI?

Which has preferable valuation & earnings, PRTC or RANI?

Is PRTC or RANI more profitable?

Summary

How does Rani Therapeutics compare to Myriad Genetics?

Do insiders and institutionals have more ownership in MYGN or RANI?

Which has better earnings and valuation, MYGN or RANI?

Does the media prefer MYGN or RANI?

Which has more volatility & risk, MYGN or RANI?

Do analysts prefer MYGN or RANI?

Is MYGN or RANI more profitable?

Summary

How does Rani Therapeutics compare to Zura Bio?

Does the media favor RANI or ZURA?

Is RANI or ZURA more profitable?

Which has more volatility and risk, RANI or ZURA?

Do analysts rate RANI or ZURA?

Do institutionals and insiders believe in RANI or ZURA?

Which has higher earnings and valuation, RANI or ZURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools